Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10659624 | 1.00 | ARG1 (0.33) | ARG1ARG2LMNATSHR | |
| SCHEMBL4634034 | 1.00 | ARG1 (0.33) | ARG1ARG2LMNATSHR | |
| SCHEMBL10989977 | 1.00 | ARG1 (0.33) | ARG1ARG2LMNATSHR | |
| Hydrochloric Acid SCHEMBL3418562 | 0.98 | ARG1 (0.32) | ARG1ARG2 | |
| SCHEMBL29113103 | 0.94 | LMNA (0.33) | LMNATSHR | |
| SCHEMBL11100097 | 0.94 | LMNA (0.33) | LMNATSHR | |
| SCHEMBL15664981 | 0.92 | ARG1 (0.34) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL25348469 | 0.90 | ARG1 (0.33) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL25348463 | 0.90 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL5791673 | 0.89 | LMNA (0.33) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271224-A | Preparation method of (2S, 4S) -4-cyclohexyl-L-proline | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-110885358-A | Vaccine for preventing tumor recurrence and metastasis and application method thereof | 浙江爱睦世医学科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| CN-108727242-A | A kind of preparation method of the trans- -4- cyclohexyl-L-PROLINE of blood-pressure drug key intermediate | 常州制药厂有限公司 | 2018-11-02 | — | — | CN | claimed |
| CN-104744511-A | Fosinopril production method | ZHANG YUN | 2015-07-01 | — | — | CN | claimed |
| US-20120142939-A1 | PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF | DIPHARMA FRANCIS S.R.L. (IT) | 2012-06-07 | — | — | US | claimed |
| EP-2460808-A1 | Process for the preparation of fosinopril and intermediates thereof | Dipharma Francis S.r.l. (IT) | 2012-06-06 | — | — | EP | claimed |
| EP-2264039-A1 | Process for the preparation of fosinopril and intermediates thereof | Dipharma Francis S.r.l. (IT) | 2010-12-22 | — | — | EP | claimed |
| US-20100297711-A1 | PROCESS FOR THE SYNTHESIS OF FOSINOPRIL AND INTERMEDIATES THEREOF | DIPHARMA FRANCIS S.R.L. (IT) | 2010-11-25 | — | — | US | claimed |
| US-7078532-B2 | Process for manufacture of fosinopril sodium | LUPIN LABORATORIES LIMITED (IN) | 2006-07-18 | — | — | US | claimed |
| US-20040225127-A1 | Process for manufacture of fosinopril sodium | LUPIN LABORATORIES LIMITED (IN) | 2004-11-11 | — | — | US | claimed |
| EP-1383779-A2 | A PROCESS FOR MANUFACTURE OF FOSINOPRIL SODIUM | LUPIN LABORATORIES LIMITED (IN) | 2004-01-28 | — | — | EP | claimed |
| WO-2002088149-A2 | A PROCESS FOR MANUFACTURE OF FOSINOPRIL SODIUM | LUPIN LABORATORIES LIMITED (IN) | 2002-11-07 | — | — | WO | claimed |
| EP-0437799-B1 | The diastereoselective preparation of phosphinate esters | SQUIBB & SONS INC (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0437799-A1 | The diastereoselective preparation of phosphinate esters | E.R. SQUIBB & SONS, INC. (US) | 1991-07-24 | — | — | EP | claimed |
| US-5008399-A | Reacting phosphinic acid ester with halo ester in presence of specific base in organic solvent, hydrogenating | E. R. SQUIBB & SONS, INC. (US) | 1991-04-16 | — | — | US | claimed |
| EP-4746915-A1 | TRIM21-BINDING MOLECULES | United Kingdom Research and Innovation (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025021697-A1 | TRIM21-BINDING MOLECULES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-01-30 | — | — | WO | disclosed |
| EP-0053902-A1 | Phosphinylalkanoyl substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-16 | — | — | EP | disclosed |
| EP-0052991-A1 | Carboxyalkyl amino acid derivatives of various substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-02 | — | — | EP | disclosed |
| US-4316905-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142939-A1 | PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF | FOS, FOSB, NPPA | ARG1 1297/4885ARG2 2480/4885LMNA 1693/4885 |
| US-20040225127-A1 | Process for manufacture of fosinopril sodium | FOS, FOSB, AGT | ARG1 1881/4885ARG2 2931/4885LMNA 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.